Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Halogenated hydrocarbon doai
Patent
1995-06-07
1999-02-23
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Halogenated hydrocarbon doai
514757, 514724, A61K 3102, A61K 31045
Patent
active
058744819
ABSTRACT:
A thermodynamically stable molecular solution providing enhanced bioavailability for lipophilic pharmaceutical agents, comprising a liquid carrier comprising one or more physiologically acceptable lipophilic fluorochemicals, and a pharmaceutically effective amount of at least one lipophilic pharmaceutical agent in said liquid carrier to form a thermodynamically stable molecular solution, optionally also including a co-solvent for facilitating solubilization of the pharmaceutical agent. Methods of making and using the molecular solution are also disclosed.
REFERENCES:
patent: 3975512 (1976-08-01), Long, Jr.
patent: 4814161 (1989-03-01), Jinks et al.
patent: 5080885 (1992-01-01), Long, Jr.
patent: 5114703 (1992-05-01), Wolf et al.
patent: 5208226 (1993-05-01), Palmer
patent: 5230884 (1993-07-01), Evans et al.
patent: 5292499 (1994-03-01), Evans et al.
patent: 5653961 (1997-08-01), McNally et al.
patent: 5653962 (1997-08-01), Akehurst et al.
patent: 5658549 (1997-08-01), Akehurst et al.
patent: 5674471 (1997-10-01), Akehurst et al.
patent: 5674472 (1997-10-01), Akehurst et al.
patent: 5674473 (1997-10-01), Purewal et al.
patent: 5676929 (1997-10-01), Akehurst et al.
patent: 5683677 (1997-11-01), Purewal et al.
patent: 5688782 (1997-11-01), Neale et al.
patent: 5736124 (1998-04-01), Akehurst et al.
patent: 5744123 (1998-04-01), Akehurst et al.
Derwent Database Publications Ltd. AN 89-136216 Abstract for JP 01083015, Mar. 28, 1989.
Arbuck, et al. "Clinical Development of Taxol" J. of National Cancer Institute Monographs 15: 11-24 (1993).
Blair, et al. "Vitreoperfusion" Arch Opthalmol 107:417-423 (1989).
Hageluken, et al. "Lipophilic .beta.-Adrenoceptor Antagonists and Local Anesthestics Are Effective Direct Activators of G-Proteins" Biochemical Pharmacology 47(10): 1789-1795 (1994).
Hughes, et al. "Effect of Acylation on the Ocular Disposition of Acyclovir II: Corneal Permeability and Anti-HSV 1 Activity of 2'-Esters in Rabbit Epithelial Keratitis" J. Ocular Pharmacology 9(4): 299-309 (1993).
Lewis, et al. "The Use of Perfluorocarbon Liquids in the Repositioning of Posteriorly Dislocated Intraocular Lenses"; Ophthalmology 100(7); 1055-1059 (1993).
Riess, Jean G. "Fluorocarbon-Based In Vivo Oxygen Transport and Delivery System" Vox Sanguinis 61: 225-239 (1991).
Shaffer, et al. "Perfluorochemical Liquid As A Respiratory Medium" Art. Cells, Blood Subs., and Immob. Biotech. 22(2): 315-326 (1994).
Shaffer, et al. "Liquid Ventilation" Pediatric Pulmonary 14: 102-109 (1992).
Tang-Liu, et al. "Lenticular Uptake and Distribution of Xenobiotics and Amino Acids" J. of Ocular Pharmacology 8(3): 267-277 (1992).
Wolfson, et al. "Pulmonary Administration of Drugs (PAD): A New Approach for Drug Delivery Using Liquid Ventilation" FASEB 4: A1105 (1990).
Yokogawa, et al. "Relationships in the Structure-Tissue Distribution of Basic Drugs in the Rabbit" Pharmaceutical Res. 7(7): 691-696 (1990).
Naito, et al. "Supplement to Perfluorochemical Blood Substitutes" Technical Information Series No. 5: 1-177 (1978).
Naito, et al. "Supplement to Perfluorochemical Blood Substitutes" Technical Information Series No. 7: 1-119 (1981).
Rowinsky, et al. "Pacitaxel (TAXOL)" New England Journal of Medicine 332(15): 1004-1014 (1995).
Evans, et al. "Formulation and in Vitro Evaluation of Presurized Inhalation Aerosols Containing Isotropic Systems of Lecithin and Water" Pharmaceutical Res. 8(5): 629-635 (1991).
Banker, et al. Modern Pharmaceutics, ed. Marcel Dekker, Inc., New York pp. 31-49 (1991).
Balasubramanian, et al. "Taxol-Lipid Interactions: Taxol-Dependent Effects on the Physical Properties of Model Membrane" Biochemistry 33: 8941-8947 (1994).
Moriguchi, et al. "Simple Method of Calculating Octanol/Water Partition Coefficient" Chem. Pharm. Bull. 40(1): 127-130 (1992).
Prescott, L.F. "The Need for Improved Drug Delivery in Clinical Practice" Novel Drug Delivery and its Therapeutic Application Chapter 1 pp. 1-7, eds. Prescott, et al. (1988).
Riess, Jean. "Hemocompatible Fluorocarbon Emulsions" Blood Compatible Materials and Devices-Perspectives Towards the 21st Century Chapter 14 pp. 237-270, eds. Sharma, et al. (1991).
Dellamary Luis A.
Ranney Helen M.
Tarara Thomas E.
Trevino Leo A.
Weers Jeffry G.
Alliance Pharmaceutical Corp.
Jarvis William R. A.
LandOfFree
Fluorochemical solutions for the delivery of lipophilic pharmace does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorochemical solutions for the delivery of lipophilic pharmace, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorochemical solutions for the delivery of lipophilic pharmace will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307643